Effects of a single dose of oral risperidone on polysomnographic measures in acute schizophrenic patients

2006 ◽  
Vol 21 (4) ◽  
pp. A21-A22
Author(s):  
N. Kotorii ◽  
N. Uchimura ◽  
M. Habukawa ◽  
T. Okawa ◽  
K. Yamamoto ◽  
...  
Keyword(s):  
Single Dose ◽  
Oral Risperidone ◽  
Schizophrenic Patients

scholarly journals Adjuvant role of testosterone in treatment of schizophrenia and its interaction with combination of first and second generation anti-psychotics, chlorpromazine and risperidone

2018 ◽  
Vol 7 (7) ◽  
pp. 1247
Author(s):  
Tarun Vijaywargia
Keyword(s):  
Single Dose ◽  
Negative Symptoms ◽  
Second Generation ◽  
Positive Symptom ◽  
Anti Psychotic ◽  
Double Blind ◽  
Oral Risperidone ◽  
Schizophrenic Patients ◽  
First And Second Generation

Background: There is great controversy about role of male sex steroid, testosterone, in mental disorders like schizophrenia. This study assessed the effectiveness of testosterone in schizophrenic patients and probes how it modulates the action of combination of first and second generation anti-psychotic medications (Chlorpromazine + Risperidone) both of which are very commonly used anti-psychotic agents in clinical psychiatric practice.Methods: It Is randomized, double-blind, Clinical study performed in Indian schizophrenic patients (new cases) in the Department of psychiatry from Feb 2003 to March 2004. Patients twelve (12) patients aged 20 to 60 years diagnosed schizophrenics according to ICD-10 Criteria who visited in outpatient department of psychiatry during study period. 12 Patient was treated with combination of oral Chlorpromazine 200mg BD + oral Risperidone 2mg BD, half of the 12 patients also received single dose of testosterone 100mg intramuscularly with above-mentioned treatment. Measure How symptomatology in schizophrenic patients affected is measured by applying various validated psychiatric scales like Brief psychiatric Rating Score (BPRS), Scale for assessment of positive symptom(SAPS), and Scale for Assessment of Negative Symptoms (SANS).Results: Single dose of Testosterone 100mg administered initially by I.M. route potentiated the reduction level in negative symptoms of schizophrenia by 119% in patients receiving oral Chlorpromazine 200mg along with oral Risperidone 4mg/day.Conclusions: In this study, Testosterone potentiated the effects of combination of oral Chlorpromazine 100mg BD + Risperidone 2mg BD, on general psychotic manifestations, positive symptoms and negative symptoms of schizophrenia, assessed on BPRS, SAPS and SANS scoring scales, however the effect is most pronounced in negative symptomology of schizophrenia.

scholarly journals Comparison of therapeutic effects of monotherapy of chlorpromazine, risperidone and their combination in newly diagnosed schizophrenic patients

2018 ◽  
Vol 7 (7) ◽  
pp. 1273
Author(s):  
Tarun Vijaywargia
Keyword(s):  
Negative Symptoms ◽  
Positive Symptom ◽  
Therapeutic Effects ◽  
Positive Symptoms ◽  
Newly Diagnosed ◽  
Anti Psychotic ◽  
Double Blind ◽  
Oral Risperidone ◽  
Beneficial Effects ◽  
Schizophrenic Patients

Background: This study evaluates and compares how negative and positive symptoms of schizophrenia were influenced with monotherapy with a first-generation anti-psychotic medication (Chlorpromazine) and a second generation anti-psychotic medication (Risperidone) and by their combination, both of which are commonly used in clinical psychiatric practice.Methods: It was randomized, double-blind, controlled clinical study performed in Indian newly diagnosed schizophrenic patients in the Department of psychiatry from Feb 2003 to March 2004. Patients 18 (eighteen) patients aged 20 to 60 years diagnosed schizophrenics according to ICD-10 Criteria who visited in outpatient department of psychiatry during study period. Three groups of 6 Patient each, group-1 - was treated with oral Chlorpromazine 100 mg 12 hly, group -2 - was treated with oral Risperidone 2mg 12 hly group 3 -was treated with combination of oral Chlorpromazine 100mg 12 hly + oral Risperidone 2 mg 12 hly. How symptomatology in schizophrenic patients affected, is measured by applying various validated psychiatric scales like Brief psychiatric Rating Score (BPRS), Scale for assessment of positive symptom(SAPS), and Scale for Assessment of Negative Symptoms (SANS).Results: the study showed that the combination therapy of oral Chlorpromazine 100 mg 12 hly + Risperidone 2mg 12 hly had reduced the overall beneficial effects which were achieved with monotherapy of both the drugs.Conclusions: In this study, the therapeutic effects of combination of oral Chlorpromazine 100 mg 12 hly + Risperidone 2 mg 12 hly found to be reduced on positive symptoms and negative symptoms of schizophrenia, assessed on SAPS and SANS scoring scales when compared with beneficial effects which were achieved with monotherapy of both the drugs.

Single Daily Dose Treatment of Psychiatric Patients with Phenothiazine Derivatives

1961 ◽  
Vol 107 (446) ◽  
pp. 104-108 ◽  
Author(s):  
F. J. Roberts
Keyword(s):  
Single Dose ◽  
Maximum Dose ◽  
Psychiatric Patients ◽  
Single Daily Dose ◽  
Total Daily Dose ◽  
Phenothiazine Derivatives ◽  
Small Reduction ◽  
Dose Administration ◽  
Daily Dose ◽  
Schizophrenic Patients

When discussing some of the problems associated with chlorpromazine (Largactil) therapy, Denber and Travis (2) point out that it is desirable that the drug be given as infrequently as is compatible with therapeutic efficacy. They found this to be twice a day. Haden (5) and Tibbits (10) report that satisfactory results can be obtained with single daily doses. While studying the single daily dose administration of drugs in a psychiatric hospital, Lara and Wells (7) found that phenothiazine compounds could reasonably be given in this way. In order to explore these reports the medication of 17 chronic, well stabilized, male schizophrenic patients was changed by giving their chlorpromazine once instead of three times a day. These patients had been on an average dosage of 200 mg. of chlorpromazine t.d.s. The dosage was altered by giving the total daily dose at one time, limiting the maximum dose to 600 mg. In some cases this resulted in a small reduction in the total dosage. The main side-effects complained of before the change were photo-sensitivity from 8 patients and drowsiness during the day from 9 patients. Because of this latter complaint the single dose was given at 9 p.m. Three weeks after the change to the single dose no alteration in symptoms or behaviour had been noted except that there were now no complaints of drowsiness during the day. Two patients complained that they disliked taking 6 large tablets at one time.

Weight Gain and Hyperprolactinemia in Schizophrenic Patients Treated During Twelve Months with Long Acting Risperidone

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1 ◽  
Author(s):  
F. Duarte Garcia ◽  
F. Duval ◽  
F. Gonzales Lopera ◽  
M.-C. Mokrani ◽  
Y. Hode ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Food Intake ◽  
Oral Risperidone ◽  
Significant Weight Gain ◽  
Length Of Treatment ◽  
Schizophrenic Patients ◽  
Long Acting ◽  
Risperidone Treatment

Background:Risperidone (RISP) may induce both elevated prolactin (PRL) levels and weight gain. the aim of this study was to evaluate body weight and mass index (BMI), and PRL modifications in schizophrenic patients treated for 1 year with long-acting risperidone (LAR).Methods:Body weight and BMI (calculated as weight in kilograms divide by height in meter squared) were determined at baseline and at endpoint in 19 schizophrenic patients (9 men and 10 women; mean[SEM] age 33.4[2.9] years). PRL levels were determined at baseline, after oral risperidone treatment (mean length of treatment: 79[30] days; mean dose: 5.8[0.5] mg daily) and during a 12 month treatment with LAR (mean dose: 50[10] mg every 2 weeks; PRL levels were measured before each injection).Results:At endpoint, a significant weight gain (Δweight: 8,1[1,4] kg) and BMI (ΔBMI: 2,9[0,5] kg/m²) was observed (both p< 0.0002). Compared with baseline, PRL levels were significantly increased (p< 0.0007; mean ΔPRL: 33[8] ng/ml). There was an association between ΔBMI>1,5 kg/m² and ΔPRL>40 ng/ ml (p< 0.04). Moreover ΔBMI was linked to the length of treatment (rho=0.47; n=19; p< 0.05).Conclusions:Our results suggest a link between weight gain and long term hyperprolactinemia in patients treated with LAR. It has been hypothesized that PRL may have a role in the regulation of food intake by increasing leptin synthesis and secretion.

The Response of Testes Cells to Low Level, Single dose Helium Particle Irradiation

1982 ◽  
Vol 40 ◽  
pp. 252-253
Author(s):  
D.E. Philpott ◽  
W. Sapp ◽  
C. Williams ◽  
J. Stevenson ◽  
S. Black ◽  
...  
Keyword(s):  
Stem Cell ◽  
Single Dose ◽  
B Cell ◽  
Cell Survival ◽  
Spermatogonial Stem Cell ◽  
Low Doses ◽  
Particle Irradiation ◽  
Stem Cell Survival ◽  
Irradiation Injury ◽  
Radio Sensitivity

Spermatogonial stem-cell survival after irradiation injury has been studied in rodents by histological counts of surviving cells. Many studies, including previous work from our laboratory, show that the spermatogonial population demonstrates a heterogeneous response to irradiation. The spermatogonia increase in radio-sensitivity as differentiation proceeds through the sequence As - Apr - A1 - A2 - A3 - A4 - In - B. The stem (As) cell is the most resistant and the B cell is the most sensitive. The purpose of this work is to investigate the response of spermatogonial cell to low doses (less than 10 0 rads) of helium particle irradiation.

Gastric Ulcers Produced by Cisplatin

1981 ◽  
Vol 39 ◽  
pp. 582-583
Author(s):  
S.K. Aggarwal ◽  
J. San Antonio
Keyword(s):  
Electron Microscopy ◽  
Single Dose ◽  
Side Effects ◽  
Antitumor Agent ◽  
Gastric Ulcers ◽  
Enzyme Cytochemistry ◽  
Intestinal Toxicity ◽  
Ovarian Cancers ◽  
Inner Surface

Cisplatin (cis-dichlorodiammineplatinum(II)) a potent antitumor agent is now available for the treatment of testicular and ovarian cancers. It is however, not free from its serious side effects including nephrotoxicity, gastro intestinal toxicity, myelosuppression, and ototoxicity. Here we now report that the drug produces peculiar bloating of the stomach in rats and induces acute ulceration.Wistar-derived rats weighing 200-250 g were administered cisplatin(9 mg/kg) ip as a single dose in 0.15 M NaCl. After 3 days the animals were sacrificed by decapitation. The stomachs were removed, the contents analyzed for pepsin and acidity. The inner surface was examined with a dissecting microscope after a moderate stretching for ulcers. Affected areas were fixed and processed for routine electron microscopy and enzyme cytochemistry.The drug treated animals kept on food and water consistently showed bloating and lesions (Fig. 1) with a frequency of 6-70 ulcers in the rumen section of the stomachs.

Sign in / Sign up

Export Citation Format

Share Document